POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 63 / 2021

Date of preparation: 2021-11-19

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Mabion enters into a quality agreement as part of its collaboration with Novavax, Inc.

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 regarding the conclusion of a commercial scale manufacturing agreement with Novavax, Inc. ("Novavax") for the years 2022-2025 ("Master Contract Manufacturing Agreement"), the Management Board of Mabion S.A. ("Company") hereby informs that on 19 November 2021, a Quality Agreement was concluded with Novavax (hereinafter: "Agreement") covering technical and regulatory arrangements for the production of the product, i.e. COVID-19 vaccine candidate antigen under the name of Nuvaxovid (formerly NVX-CoV2373), including relevant GMP (Good Manufacturing Practice) standards. The Agreement is effective as of the date of its conclusion until the end of the Manufacturing Agreement, subject to necessary updates.

The Agreement covers the obligations and technical and regulatory arrangements required in respect of the manufacture, testing, storage, and shipment of the product. It also defines the rules of cooperation between the departments involved in the implementation thereof.

The conclusion of the Agreement is an important stage as part of the implementation of the Manufacturing Agreement. Immediately after the Agreement is concluded, the Company will submit, already today, a notification to the Chief Pharmaceutical Inspectorate ("GIF") on the conclusion of the above-mentioned Agreement. The next step will consist in submitting a notification to the GIF on the change of manufacturing conditions, based on which the Company will be able to start production. The Company will inform about them in a current report.